Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.52 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.52 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.52 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.52 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CTSD | P07339 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL741751 | 0.97 | MEN1 (0.58) | MEN1KMT2ACTSDTDP1L3MBTL1 | |
| Acetic Acid SCHEMBL9853044 | 0.91 | MEN1 (0.53) | MEN1KMT2ACTSDTDP1L3MBTL1 | |
| Thiourea SCHEMBL29061164 | 0.87 | MEN1 (0.50) | MEN1KMT2ACTSDTDP1L3MBTL1 | |
| SCHEMBL28038711 | 0.87 | KMT2A (0.54) | MEN1KMT2ACTSDTDP1L3MBTL1 | |
| SCHEMBL2205442 | 0.85 | SLC6A2 (0.54) | MEN1KMT2ACTSDTDP1L3MBTL1 | |
| SCHEMBL7758852 | 0.85 | MEN1 (0.77) | MEN1KMT2ACTSDTDP1L3MBTL1 | |
| SCHEMBL28807102 | 0.85 | MEN1 (0.53) | MEN1KMT2ACTSDTDP1L3MBTL1 | |
| SCHEMBL4481763 | 0.85 | MEN1 (0.53) | MEN1KMT2ACTSDTDP1L3MBTL1 | |
| SCHEMBL28741668 | 0.85 | MEN1 (0.49) | MEN1KMT2ACTSDTDP1L3MBTL1 | |
| SCHEMBL4505807 | 0.85 | HTT (0.56) | MEN1KMT2ACTSDTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105481736-A | Phenylglycine-containing cinnamamide histone deacetylase inhibitor, and preparation method and application thereof | UNIV SHANDONG | 2016-04-13 | — | — | CN | claimed |
| CN-102641265-A | Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome | TIOGA PHARMACEUTICALS INC | 2012-08-22 | — | — | CN | claimed |
| CN-101677997-B | Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome | TIOGA PHARMACEUTICALS INC | 2012-05-09 | — | — | CN | claimed |
| US-20230398093-A1 | ANTI-METHANOGENIC LOVASTATIN ANALOGS OR DERIVATIVES AND USES THEREOF | CEDARS-SINAI MEDICAL CENTER (US) | 2023-12-14 | — | — | US | disclosed |
| CN-105481736-A | Phenylglycine-containing cinnamamide histone deacetylase inhibitor, and preparation method and application thereof | UNIV SHANDONG | 2016-04-13 | — | — | CN | disclosed |
| CN-102641265-A | Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome | TIOGA PHARMACEUTICALS INC | 2012-08-22 | — | — | CN | disclosed |
| CN-101677997-B | Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome | TIOGA PHARMACEUTICALS INC | 2012-05-09 | — | — | CN | disclosed |
| CN-1119147-C | Kappa-opiate agonists for inflammatory bowel disorders | MERCK PATENT GMBH (DE) | 2003-08-27 | — | — | CN | disclosed |
| EP-0564924-B1 | 2-Oxoethyl derivatives as immunosuppressants | BAYER AG (US) | 1998-09-09 | — | — | EP | disclosed |
| CN-1145781-A | Kappa-opiate agonists for inflammatory bowel disorders | MERCK PATENT GMBH (DE) | 1997-03-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398093-A1 | ANTI-METHANOGENIC LOVASTATIN ANALOGS OR DERIVATIVES AND USES THEREOF | HMGCR, SI, SLC10A2 | HDAC3 2777/4885HDAC4 2151/4885HDAC1 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.